Vor Bio

VOR · Nasdaq · United States

Share price · VOR

$17.83-5.45 (-23.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 794K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VOR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Sep 2026-12.0%
  2. 2 Sep 2026+9.4%
  3. 30 Jul 2026+11.5%
  4. 21 Jul 2026+14.9%
  5. 2 Jul 2026+12.0%

    Nothing announced by VOR that day or the session before.

  6. 29 Jun 2026+15.5%
  7. 27 May 2026+10.1%
  8. 31 Mar 2026+21.4%

Share of unusual movement by asset

For each asset, the share of VOR's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Telitacicept
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—99%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
BAFF / APRILProtein / enzyme therapeutic
Rheumatoid ArthritisIgA NephropathySjögren's DiseaseMyasthenia Gravis
Generalized Myasthenia Gravis

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TelitaciceptPhase 3Myasthenia Gravis, Ocular
Est. primary completion 2026-12-31 · NCT07249632 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
TelitaciceptPhase 3Generalized Myasthenia Gravis
Est. primary completion 2027-03 · NCT06456580 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
TelitaciceptPhase 3Primary Sjogren's Disease
Est. primary completion 2028-12 · NCT07404865 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
TelitaciceptPhase 3CTD-ILD
Est. primary completion 2029-05-31 · NCT07495033 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 October 2025Topline resultTelitaciceptPhase III Sjögren's Syndrome trial meets primary endpoint
19 September 2025Filing acceptedTelitaciceptChina BLA for Sjögren's Syndrome accepted by CDE
CN, NMPA · Source ↗
13 August 2025Topline resultTelitaciceptChina Phase 3 in primary Sjögren's (NCT05673993) met its primary endpoint
RemeGen Co., Ltd · Source ↗
27 May 2025ApprovalTelitaciceptTelitacicept approved in China for generalized myasthenia gravis
CN, NMPA · Source ↗
8 April 2025Topline resultTelitaciceptChina Phase 3 in generalized myasthenia gravis (NCT05737160): MG-ADL change -5.74 vs -0.91 with placebo at Week 24
RemeGen Co., Ltd · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$35M$79M+ $403M short-term inv.$87M-$33M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$26M$108M+ $358M short-term inv.$63M-$25M operating cash flowreport ↗
2026-Q1—$18M$170M+ $322M short-term inv.$220M-$38M operating cash flowreport ↗
2025-Q3—$14M$160M+ $10M short-term inv.$813M-$54M operating cash flowreport ↗
2025-Q2—$262M$191M+ $10.0M short-term inv.$1.6B-$35M operating cash flowreport ↗
2025-Q1—$27M$50M+ $10.0M short-term inv.$32M-$31M operating cash flowreport ↗
2024-Q3—$22M$53M+ $10M short-term inv.$28M-$23M operating cash flowreport ↗
2024-Q2—$22M$76M+ $9.9M short-term inv.$28M-$22M operating cash flowreport ↗
2024-Q1—$24M$45M+ $63M short-term inv.$31M-$30M operating cash flowreport ↗
2023-Q3—$28M$45M+ $115M short-term inv.$33M-$28M operating cash flowreport ↗
2023-Q2—$24M$32M+ $155M short-term inv.$30M-$24M operating cash flowreport ↗
2023-Q1—$22M$42M+ $168M short-term inv.$28M-$24M operating cash flowreport ↗
2022-Q3—$17M$61M+ $75M short-term inv.$24M-$19M operating cash flowreport ↗
2022-Q2—$15M$63M+ $88M short-term inv.$22M-$25M operating cash flowreport ↗
2022-Q1—$15M$90M+ $92M short-term inv.$23M-$23M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$322M$396M+ $59M short-term inv.$174M-$143M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$93M$82M+ $10.0M short-term inv.$29M-$100M operating cash flowreport ↗
2023-FY—$94M$31M+ $106M short-term inv.$29M-$100M operating cash flowreport ↗
2022-FY—$65M$58M+ $173M short-term inv.$23M-$85M operating cash flowreport ↗
2021-FY—$48M$120M+ $88M short-term inv.$17M-$69M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($49.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Sokolove Jeremy Brett · Chief Medical OfficerTax withholding1,917$19.25$37KForm 4
2026-10-02RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise500$12.80$6KForm 4
2026-10-02RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise (derivative)500——Form 4
2026-08-24RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise1,500$3.74$6KForm 4
2026-08-24RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise (derivative)1,500——Form 4
2026-07-16RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise2,100,000$0.00$4KForm 4
2026-07-16RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale213$19.75$4KForm 4
2026-07-16RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOption exercise (derivative)2,100,000$5.00$10.5MForm 4